SPARTANBURG, S.C., Jan. 18, 2011 /PRNewswire/ — Norgenix
Pharmaceuticals, LLC (www.norgenixpharma.com),
a wholly owned subsidiary of Spartanburg-based J M Smith
Corporation, and Fertility Focus Limited (www.fertility-focus.com)
today announced a partnership for the co-promotion of the
Fertiloscope™, a CE marked and 510(k) approved
surgical instrument for the early diagnosis and immediate
corrective surgery of physical causes of female infertility.
Norgenix has exclusive rights to market and distribute the
Fertiloscope™ in the United States, as well as US
territories and military bases. The product will benefit from the
strategic support of Glenveigh Medical (www.glenveigh.com) as well,
with whom Norgenix has an existing alliance in the U.S. to promote
medical devices developed by Glenveigh.
Norgenix and Fertility Focus also announced a strategic alliance
and revealed its first medical device co-promotion, the
Fertiloscope™. Norgenix is a North American
specialty pharmaceutical, medical device and biotechnology company
that engages in the development, commercialization, and sales of
products in the women’s health arena. Norgenix is licensed to sell,
market, and distribute prescription drug products and medical
devices in all 50 U.S. states. Fertility Focus is a United Kingdom
based company that develops devices aimed at the infertility
market.
Developed by the eminent French surgeon Dr. Antoine Watrelot,
the Fertiloscope™, is a novel laparoscope for
minimally invasive trans-vaginal use in a procedure that is known
as Fertiloscopy. The Fertiloscope™ is the only
method of primary screening that provides gold standard accuracy in
a day-case or office setting. This relatively new surgical
technique is used for the early diagnosis and immedi
‘/>”/>
SOURCE